Please wait while we load the requested 10-Q report or click the link below:
EyePoint Pharmaceuticals Reports Second Quarter 2019 Financial Results and
Highlights Recent Company Progress
Company reports total revenue of $7.2 million
- Two commercial product launches in U.S. are underway for DEXYCU® and YUTIQ® with 43 sales
reps actively targeting uveitis specialists, cataract surgeons and ambulatory surgical centers
YUTIQ receives specific and permanent J Code, effective October 1, 2019
- Over 400 physicians have completed a certification program and are now certified to purchase
and administer DEXYCU
Management to host a conference call and webcast today at 8:30 AM ET
WATERTOWN, Mass., August 7, 2019 - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial results for the second quarter ended June 30, 2019 and highlighted recent commercial and corporate developments.
The physician feedback to date from our two commercial product launches, YUTIQ® and DEXYCU®, has been very positive, and we have seen a solid uptake in treatment volume along with tremendous progress in market access, said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. Our field force has received similar reception and eagerness to meet from physicians in the office setting for YUTIQ and at ambulatory surgery centers (ASCs) for DEXYCU. Our efforts on training and certifying physicians during our phased launch of DEXYCU are generating sales momentum with a solid start in July, as evidenced by the number of ASCs purchasing product for the first time, as well as repeat purchases. YUTIQ continues to address a large unmet need for patients afflicted with chronic non-infectious posterior segment uveitis and July sales remain on a solid upward trajectory with the number of ordering physicians increasing month over month. With the recently accelerated October 1, 2019 effective date of a permanent and specific J code for YUTIQ, J7413, payor approval and reimbursement will soon become even easier and more streamlined.
Ms. Lurker continued, Physicians are now actively seeing the clinical results of both YUTIQ and DEXYCU with their patients and to date have experienced positive efficacy and safety results as seen in the pivotal clinical studies. We are very proud to have launched our two exciting ophthalmic products, YUTIQ and DEXYCU, and to bring these innovative products to patients in need.
The following information was filed by Eyepoint Pharmaceuticals, Inc. (EYPT) on Wednesday, August 7, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Eyepoint Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Eyepoint Pharmaceuticals, Inc..